Gallaway Kathryn E, Ahn Junho, Callan Alexandra K
Department of Orthopaedic Surgery, UT Southwestern Medical Center, Dallas, TX, USA.
Sarcoma. 2020 Feb 14;2020:1283080. doi: 10.1155/2020/1283080. eCollection 2020.
Pediatric bone and soft tissue sarcomas are rare; therefore, national registries are essential tools for orthopedic oncology research. Past studies provide excellent data on long-term prognosis and survival trends but fail to examine treatment-specific morbidity. The aim of this study is to use a national registry to describe patient demographics, comorbidities, and adverse events in the first thirty days following surgical management of pediatric bone and soft tissue sarcomas.
A retrospective review of patients in the American College of Surgeons National Surgical Quality Improvement Program-Pediatrics database (NSQIP-P) was performed. The cohort was partitioned by tumor origin (bone versus soft tissue) and tumor location (axial versus appendicular).
One-hundred ninety-two patients were identified. Bone sarcomas were more common (71.9%) and predominately appendicular (62.3%), while soft tissue sarcomas were predominately axial (77.8%). The overall complication rate was 8.9%. The most frequent etiologies were wound dehiscence (3.6%) and infectious complications such as surgical site infections (2.6%), pneumonia (1.6%), urinary tract infections (1.6%), and colitis (1.0%). Twenty-four percent of patients experienced bleeding requiring transfusion. The unplanned readmission rate was 12.5% (3.6% related to principle procedure), and the unplanned reoperation rate was 4.7% (4.2% related to principle procedure). The mortality rate was 1.0%. Neoadjuvant chemotherapy was associated with higher rates of wound dehiscence and infectious complications. There were no differences in adverse events with respect to tumor origin or location.
Approximately 1 in 11 pediatric patients will experience a complication in the first thirty days following surgery. However, perioperative mortality remains low. This study represents the first comprehensive review of pediatric bone and soft tissue sarcoma surgery in the NSQIP-P database. As the case volume of NSQIP-P continues to grow, NSQIP-P has the potential to become a powerful tool for pediatric orthopedic oncology research.
儿童骨肉瘤和软组织肉瘤较为罕见;因此,国家登记系统是骨科肿瘤学研究的重要工具。既往研究提供了关于长期预后和生存趋势的出色数据,但未能考察特定治疗的发病率。本研究的目的是利用国家登记系统描述儿童骨肉瘤和软组织肉瘤手术治疗后前30天内的患者人口统计学特征、合并症及不良事件。
对美国外科医师学会国家外科质量改进计划-儿科数据库(NSQIP-P)中的患者进行回顾性研究。队列按肿瘤起源(骨与软组织)和肿瘤部位(轴向与附属)进行划分。
共识别出192例患者。骨肉瘤更为常见(71.9%),且主要位于附属部位(62.3%),而软组织肉瘤主要位于轴向(77.8%)。总体并发症发生率为8.9%。最常见的病因是伤口裂开(3.6%)和感染性并发症,如手术部位感染(2.6%)、肺炎(1.6%)、尿路感染(1.6%)和结肠炎(1.0%)。24%的患者发生需要输血的出血情况。计划外再入院率为12.5%(3.6%与主要手术相关),计划外再次手术率为4.7%(4.2%与主要手术相关)。死亡率为1.0%。新辅助化疗与更高的伤口裂开率和感染性并发症发生率相关。不良事件在肿瘤起源或部位方面无差异。
约每11名儿童患者中就有1例在术后前30天内会发生并发症。然而,围手术期死亡率仍然较低。本研究是NSQIP-P数据库中对儿童骨肉瘤和软组织肉瘤手术的首次全面回顾。随着NSQIP-P病例数量的持续增加,NSQIP-P有潜力成为儿童骨科肿瘤学研究的有力工具。